Exelixis, Inc. (Nasdaq: EXEL) announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Leerink Bumps PT on Exelixis (EXEL) Up to $16 Following Latest Cabozantinib DataOctober 11, 2016 6:27 AM Piper Jaffray Upgrades Exelixis (EXEL) to OverweightOctober 10, 2016 9:09 AM Exelixis (EXEL) Bullish View Reiterated at Leerink Following Positive CABOSUN DataOctober 10, 2016 7:40 AM Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016October 10, 2016 2:15 AM